학술논문
1925P Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S1035-S1035
Subject
Language
ISSN
0923-7534